Patient treatment preferences study version 1.0
Understanding patient treatment preferences for muscle invasive bladder cancer: A discrete choice experiment.
Guy's & St Thomas' NHS Foundation Trust
Duration of Study in the UK
0 years, 10 months, 25 days
Bladder cancer is the 11th most common cancer in the UK (both male and female) yet there is proportionally less research undertaken compared to other types of cancer. Tumours that are just confined to the inner layer are classified as non-muscle invasive bladder cancer (NMIBC), and tumours that progress deeper into the detrusor muscle are classified as muscle invasive bladder cancer (MIBC). At the time of diagnosis for patients approximately 75% are non-muscle invasive and 25% are muscle-invasive/metastatic. MIBCs are often treated with intensive and combined treatments due to their aggressive disease progression and tendency to spread. Current best clinical practice is to offer patients with MIBC a radical cystectomy with lymph node dissection, however not all patients are suitable for surgery, or refuse it. In select cases patients may be offered trimodality therapy, a combination of minor surgery, radiotherapy, and chemotherapy. Through the Patient Treatment Preferences study, we aim to better understand the most important factors for patients when deciding on the type of treatment they receive for MIBC. This will help us improve our knowledge of patient preferences and what “trade-offs” patients are willing to accept. The study consists of a discrete choice experiment (DCE), a type of questionnaire used to elicit preferences in the absence of data.
South Central - Hampshire A Research Ethics Committee
Date of REC Opinion
10 Jun 2022
Further Information Favourable Opinion